The safety profile of DUPIXENT in adults and pediatric patients 6 months to 17 years of age through Week 16 was similar. The long-term safety profile of DUPIXENT ± TCS across multiple age groups was assessed in an open-label extension study (AD-1434). DUPIXENT demonstrated a generally consistent safety profile across infants to preschoolers, children, adolescents, and adults. In AD-1434, hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) was reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.1